Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
Although several parameters are useful for risk stratification of patients with acute myeloid leukaemia (AML), there are no firm criteria for predicting response to induction treatment of individual patients. Daily flow cytometry (FC) analysis, carried out during induction treatment in 30 AML patients, showed that the clearance of blasts from peripheral blood (PBC) correlated closely with response, as assessed by bone marrow FC on day 14, and by morphologic analysis at haematopoietic recovery. Therefore, a major treatment outcome can be predicted very early in AML patients, thus providing an opportunity for tailoring treatment modalities from the outset.
Gianfaldoni
Giacomo
G
Department of Haematology, Azienda Ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy. ggianfaldoni@libero.it
Mannelli
Francesco
F
Baccini
Michela
M
Antonioli
Elisabetta
E
Leoni
Franco
F
Bosi
Alberto
A
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy* / Q000276:immunology; D001853:Bone Marrow / Q000276:immunology; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D012074:Remission Induction
D003561:Cytarabine; D015255:Idarubicin